(19)
(11) EP 2 606 061 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.09.2017 Bulletin 2017/39

(45) Mention of the grant of the patent:
09.08.2017 Bulletin 2017/32

(21) Application number: 11744024.8

(22) Date of filing: 16.08.2011
(51) International Patent Classification (IPC): 
C07K 14/435(2006.01)
(86) International application number:
PCT/EP2011/064086
(87) International publication number:
WO 2012/022742 (23.02.2012 Gazette 2012/08)

(54)

BINDING PROTEINS FOR HEPCIDIN

BINDUNGSPROTEINE FÜR HEPCIDIN

PROTÉINES SE LIANT À L'HEPCIDINE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.08.2010 US 374199 P

(43) Date of publication of application:
26.06.2013 Bulletin 2013/26

(60) Divisional application:
17185231.2

(73) Proprietor: Pieris Pharmaceuticals GmbH
85354 Freising-Weihenstephan (DE)

(72) Inventors:
  • TRENTMANN, Stefan
    85391 Allershausen (DE)
  • MATSCHINER, Gabriele
    80333 Muenchen (DE)
  • SKERRA, Arne
    85354 Freising (DE)
  • HUELSMEYER, Martin
    85395 Wolfersdorf (DE)
  • GILLE, Hendrik
    80634 München (DE)
  • JENSEN, Kristian
    84028 Landshut (DE)
  • BEL AIBA, Rachida Siham
    80469 München (DE)
  • CHRISTIAN, Hans-Juergen
    85368 Moosburg (DE)
  • HOHLBAUM, Andreas
    85307 Paunzhausen (DE)

(74) Representative: Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB 
Landsberger Straße 98
80339 München
80339 München (DE)


(56) References cited: : 
WO-A1-2009/058797
WO-A2-2006/056464
WO-A2-03/029463
   
  • Anonymous: "Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin® PRS-080 Hepcidin Antagonist Drug Program", Pieris AG: News and Events , 23 May 2011 (2011-05-23), XP002661794, Retrieved from the Internet: URL:http://www.pieris-ag.com/news-events/2 001-05-23-Pieris-Announces-Preclinical-In- Vitro-and-In-Vivo-Data.php [retrieved on 2011-10-20]
  • GEBAUER M ET AL: "Engineered protein scaffolds as next-generation antibody therapeutics", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 13, no. 3, 1 June 2009 (2009-06-01), pages 245-255, XP026285197, CURRENT BIOLOGY LTD, LONDON, GB ISSN: 1367-5931, DOI: 10.1016/J.CBPA.2009.04.627 [retrieved on 2009-06-06]
  • D. SCHONFELD ET AL: "An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 20, 19 May 2009 (2009-05-19) , pages 8198-8203, XP055010048, ISSN: 0027-8424, DOI: 10.1073/pnas.0813399106
  • JOLANTA MALYSZKO ET AL: "Neutrophil Gelatinase-Associated Lipocalin and Hepcidin: What Do They Have in Common and Is There a Potential Interaction?", KIDNEY AND BLOOD PRESSURE RESEARCH, vol. 33, no. 2, 1 January 2010 (2010-01-01), pages 157-165, XP055010065, ISSN: 1420-4096, DOI: 10.1159/000315436
  • SKERRA A: "'ANTICALINS': A NEW CLASS OF ENGINEERED LIGNAD-BINDING PROTEINS WITH ANTIBODY-LIKE PROPERTIES", REVIEWS IN MOLECULAR BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 4, 1 June 2001 (2001-06-01), pages 257-275, XP001079016, ISSN: 1389-0352, DOI: 10.1016/S1389-0352(01)00020-4 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).